Brokerages Expect Medpace Holdings Inc (MEDP) Will Post Earnings of $0.60 Per Share

Wall Street brokerages expect Medpace Holdings Inc (NASDAQ:MEDP) to report $0.60 earnings per share for the current quarter, Zacks reports. Six analysts have made estimates for Medpace’s earnings, with the highest EPS estimate coming in at $0.65 and the lowest estimate coming in at $0.54. Medpace also posted earnings of $0.60 per share in the same quarter last year. The business is scheduled to issue its next earnings results after the market closes on Monday, April 29th.

On average, analysts expect that Medpace will report full year earnings of $2.64 per share for the current year, with EPS estimates ranging from $2.63 to $2.66. For the next financial year, analysts forecast that the business will post earnings of $2.96 per share, with EPS estimates ranging from $2.87 to $3.08. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow Medpace.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 25th. The company reported $0.76 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.69 by $0.07. The company had revenue of $192.12 million during the quarter, compared to the consensus estimate of $184.66 million. Medpace had a return on equity of 17.66% and a net margin of 11.27%. Medpace’s revenue was up 70.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.39 EPS.

MEDP has been the subject of several analyst reports. Zacks Investment Research downgraded Medpace from a “buy” rating to a “hold” rating in a report on Wednesday, January 9th. ValuEngine upgraded Medpace from a “hold” rating to a “buy” rating in a report on Thursday, January 10th. BidaskClub upgraded Medpace from a “buy” rating to a “strong-buy” rating in a report on Friday, January 25th. TheStreet downgraded Medpace from a “b” rating to a “c” rating in a report on Friday, March 22nd. Finally, Wolfe Research initiated coverage on Medpace in a report on Tuesday, April 2nd. They issued an “outperform” rating for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. Medpace has an average rating of “Buy” and an average price target of $55.33.

MEDP traded up $0.30 during trading on Wednesday, hitting $54.40. The company’s stock had a trading volume of 5,877 shares, compared to its average volume of 410,905. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.69 and a current ratio of 0.69. The company has a market capitalization of $1.95 billion, a PE ratio of 21.02, a price-to-earnings-growth ratio of 1.71 and a beta of 1.62. Medpace has a twelve month low of $35.00 and a twelve month high of $71.66.

In related news, CFO Jesse J. Geiger sold 25,037 shares of the company’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $60.00, for a total transaction of $1,502,220.00. Following the completion of the sale, the chief financial officer now directly owns 25,037 shares of the company’s stock, valued at approximately $1,502,220. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Medpace Investors, Llc sold 172,311 shares of the company’s stock in a transaction on Thursday, January 31st. The stock was sold at an average price of $63.59, for a total transaction of $10,957,256.49. Following the sale, the insider now directly owns 8,025,349 shares of the company’s stock, valued at $510,331,942.91. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 679,858 shares of company stock valued at $43,067,867. Insiders own 29.50% of the company’s stock.

A number of institutional investors have recently made changes to their positions in MEDP. BlackRock Inc. boosted its position in Medpace by 82.2% during the 4th quarter. BlackRock Inc. now owns 4,158,359 shares of the company’s stock worth $220,103,000 after purchasing an additional 1,876,296 shares during the period. Pendal Group Ltd boosted its position in Medpace by 10,018.7% during the 4th quarter. Pendal Group Ltd now owns 1,593,387 shares of the company’s stock worth $73,338,000 after purchasing an additional 1,577,640 shares during the period. Vanguard Group Inc boosted its position in Medpace by 63.6% during the 3rd quarter. Vanguard Group Inc now owns 2,897,702 shares of the company’s stock worth $173,601,000 after purchasing an additional 1,126,649 shares during the period. Vanguard Group Inc. boosted its position in Medpace by 63.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,897,702 shares of the company’s stock valued at $173,601,000 after buying an additional 1,126,649 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of Medpace by 130.9% in the 4th quarter. Bank of New York Mellon Corp now owns 753,303 shares of the company’s stock valued at $39,872,000 after purchasing an additional 427,062 shares in the last quarter. 82.84% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.

Further Reading: What is the Quick Ratio?

Get a free copy of the Zacks research report on Medpace (MEDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.